Skip to content
Lactic acid
Phexxi, Prismasol (lactic acid) is a small molecule pharmaceutical. Lactic acid was first approved as Prismasol bgk 2/0 in plastic container on 2006-10-25. It is used to treat dermatitis and facial dermatoses in the USA. It is known to target hydroxycarboxylic acid receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Combinations
Phexxi, Prismasol
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium chloride
+
Dextrose
+
Lactic acid
+
Magnesium chloride
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
Tradename
Company
Number
Date
Products
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINERBaxterN-021703 RX2008-10-10
1 products, RLD, RS
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINERBaxterN-021703 RX2008-10-10
1 products, RLD, RS
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINERBaxterN-021703 RX2008-10-10
1 products, RLD, RS
PRISMASOL BGK 2/0 IN PLASTIC CONTAINERBaxterN-021703 RX2006-10-25
1 products, RLD, RS
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINERBaxterN-021703 RX2006-10-25
1 products, RLD, RS
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINERBaxterN-021703 RX2006-10-25
1 products, RLD, RS
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINERBaxterN-021703 RX2006-10-25
1 products, RLD, RS
Show 8 discontinued
Citric acid
+
Lactic acid
+
Potassium bitartrate
Tradename
Company
Number
Date
Products
PHEXXIEvofem BiosciencesN-208352 RX2020-05-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
phexxiNew Drug Application2020-07-16
phoxillum prismasolNew Drug Application2018-11-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
dermatitisHP_0011123D003872L30.9
facial dermatoses—D005148—
Agency Specific
FDA
EMA
Expiration
Code
CITRIC ACID / LACTIC ACID / POTASSIUM BITARTRATE, PHEXXI, EVOFEM INC
2023-05-22NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Citric Acid / Lactic Acid / Potassium Bitartrate, Phexxi, Evofem Inc
105688552033-03-15U-1
113379892033-03-15U-1
114396102033-03-15DS, DP
67062762023-09-06DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07F: Antidiarrheal microorganisms
— A07FA: Antidiarrheal microorganisms
— A07FA01: Lactic acid producing organisms
— A07FA51: Lactic acid producing organisms, combinations
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AD: Organic acids, gynecological
— G01AD01: Lactic acid
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pre-eclampsiaD011225EFO_0000668O143325112
Pregnancy-induced hypertensionD046110O13—236—10
HypotensionD007022EFO_0005251I95———2—2
LaparoscopyD010535———1—1
Ischemic strokeD000083242———1—1
BronchoscopyD001999———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10221—36
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9—3——14
Cerebral hemorrhageD002543—2——13
Blood pressureD001794EFO_0004325—2———2
Postoperative painD010149G89.1811———1
Heart rateD006339EFO_0004326—1———1
ProteinuriaD011507HP_0000093R8011———1
CraniotomyD00339911———1
Drug-related side effects and adverse reactionsD064420T88.7—1———1
Tobacco use disorderD014029F17—1———1
Cocaine-related disordersD019970F14—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Morbid obesityD009767EFO_00010741————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intracranial hemorrhagesD020300EFO_0000551I62————11
Pregnancy rateD018873————11
Low cardiac outputD002303————11
High cardiac outputD016534————11
Intratracheal intubationD007442————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLACTIC ACID
INN—
Description
2-hydroxypropanoic acid is a 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group. It has a role as a Daphnia magna metabolite and an algal metabolite. It is functionally related to a propionic acid. It is a conjugate acid of a lactate.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(O)C(=O)O
Identifiers
PDB—
CAS-ID50-21-5
RxCUI1314409
ChEMBL IDCHEMBL1200559
ChEBI ID78320
PubChem CID612
DrugBankDB04398
UNII ID—
Target
Agency Approved
No data
Alternate
HCAR1
HCAR1
Organism
Homo sapiens
Gene name
HCAR1
Gene synonyms
GPR104, GPR81, HCA1
NCBI Gene ID
27198
Protein name
hydroxycarboxylic acid receptor 1
Protein synonyms
G protein-coupled receptor 104, G-protein coupled receptor 104, G-protein coupled receptor 81, hydroxy-carboxylic acid receptor 1, lactate receptor 1, T-cell activation G protein-coupled receptor
Uniprot ID
Q9BXC0
Mouse ortholog
Hcar1 (243270)
hydroxycarboxylic acid receptor 1 (B9EJ36)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 172,828 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,653 adverse events reported
View more details